Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 3Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 142INDUSTRY 30OTHER_GOV 5NIH 5NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Breast Neoplasms 179Leukemia 162Lymphoma 116Lung Neoplasms 107Carcinoma, Non-Small-Cell Lung 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 97Central Nervous System Neoplasms 84Sarcoma 82Prostatic Neoplasms 81Ovarian Neoplasms 76Colorectal Neoplasms 71Head and Neck Neoplasms 70Leukemia, Myeloid, Acute 60Squamous Cell Carcinoma of Head and Neck 54Rectal Neoplasms 54Neuroblastoma 52Colonic Neoplasms 52Multiple Myeloma 51Uterine Cervical Neoplasms 47Brain Neoplasms 46Lymphoma, Large B-Cell, Diffuse 45Leukemia, Lymphocytic, Chronic, B-Cell 41Carcinoma, Ovarian Epithelial 41Burkitt Lymphoma 41Astrocytoma 40Glioblastoma 39Fallopian Tube Neoplasms 39Neoplasm Metastasis 38Congenital Abnormalities 37Lymphoma, Follicular 36

Interventions

Cyclophosphamide 3carfilzomib 2Dexamethasone 2deltacortene 1Melphalan 1Calcium Dobesilate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × NETWORK × Disease × Clear all
NCT01857115 2024-11-13

wCCyd

European Myeloma Network B.V.

Phase 1/2 Completed
63 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT01190787 2024-01-23

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

European Myeloma Network B.V.

Phase 2 Completed
150 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT02204241 2023-07-03

CCD

European Myeloma Network B.V.

Phase 1/2 Completed
36 enrolled
Plasma cell

Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡